Loading...
Loading...
ASRT| Name | Value |
|---|---|
| Revenues | 29.2M |
| Cost of Revenue | 7.5M |
| Gross Profit | 21.7M |
| Operating Expense | 24.7M |
| Operating I/L | -3.0M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.9M |
| Pretax | -2.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -2.9M |
Assertio Holdings, Inc. is a specialty pharmaceutical company that focuses on neurology, hospital, pain, and inflammation medicines. Its product portfolio includes INDOCIN for rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, and gouty arthritis; CAMBIA for migraine treatment; Zipsor for acute pain relief; SPRIX for moderate to severe pain management; and Otrexup for rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. The company generates revenue by selling these pharmaceutical products to healthcare providers and patients, addressing the needs of individuals suffering from various painful and inflammatory conditions.
